Dyax (DYAX), Novellus Enter KALBITOR Development Collaboration

January 31, 2013 7:01 AM EST Send to a Friend
Get Alerts DYAX Hot Sheet
Trade DYAX Now!
Join SI Premium – FREE
Dyax Corp. (NASDAQ: DYAX) and Novellus Biopharma AG (Novellus) announced today a strategic partnership for the development and commercialization of KALBITOR® (ecallantide) for the treatment of hereditary angioedema (HAE) and other angioedema indications in select regions in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico and Venezuela. KALBITOR is marketed in United States for the treatment of acute attacks of HAE in patients 16 years of age and older.

Under the terms of the exclusive license agreement, Dyax will receive an upfront payment and is eligible to receive future sales milestones. Dyax is also eligible to receive royalties on net product sales. Novellus is solely responsible for all costs associated with necessary development, regulatory activities, and the commercialization of KALBITOR in the covered territories. Additionally, Novellus will purchase drug product from Dyax on a cost-plus basis for commercial supply.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment